Intellia Announces $150M+ Public Stock Offering to Fund BLA Submission and Pre-Commercial Activities for Lonvo-z

On the same day as the Phase 3 HAELO topline announcement, Intellia Therapeutics announces a proposed underwritten public offering of common stock to raise capital for regulatory filing, pre-commercial buildout, and operational expenses related to lonvo-z's anticipated BLA submission. The offering signals investor confidence in the Phase 3 results and the company's commercial readiness timeline. Underwriters are led by Jefferies, Goldman Sachs, and Citigroup. (Final pricing completed April 29, 2026: 16,744,187 shares at $10.75/share for gross proceeds of approximately $180 million, plus underwriter over-allotment option for up to 2,511,628 additional shares.)